Newbridge Financial Services Group Inc. Invests $37,000 in Amarin Co. plc (NASDAQ:AMRN)

Newbridge Financial Services Group Inc. bought a new position in shares of Amarin Co. plc (NASDAQ:AMRNFree Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 41,900 shares of the biopharmaceutical company’s stock, valued at approximately $37,000.

Several other institutional investors also recently bought and sold shares of AMRN. Raymond James Financial Services Advisors Inc. increased its position in shares of Amarin by 35.7% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 649,152 shares of the biopharmaceutical company’s stock worth $597,000 after acquiring an additional 170,670 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Amarin by 16.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 122,498 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 17,613 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Amarin by 18.9% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 129,200 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 20,500 shares during the period. LCM Capital Management Inc grew its position in shares of Amarin by 103.4% during the third quarter. LCM Capital Management Inc now owns 704,159 shares of the biopharmaceutical company’s stock worth $648,000 after buying an additional 358,000 shares in the last quarter. Finally, Hayek Kallen Investment Management increased its stake in shares of Amarin by 83.6% during the third quarter. Hayek Kallen Investment Management now owns 622,643 shares of the biopharmaceutical company’s stock worth $573,000 after buying an additional 283,564 shares during the period. 22.25% of the stock is owned by institutional investors and hedge funds.

Amarin Stock Performance

Shares of NASDAQ:AMRN traded up $0.02 during trading hours on Tuesday, reaching $0.90. The stock had a trading volume of 484,351 shares, compared to its average volume of 1,799,937. Amarin Co. plc has a 1 year low of $0.65 and a 1 year high of $1.49. The firm’s 50 day moving average is $0.91 and its 200-day moving average is $0.96. The stock has a market capitalization of $368.21 million, a price-to-earnings ratio of -7.47 and a beta of 1.96.

Amarin (NASDAQ:AMRNGet Free Report) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. The firm had revenue of $56.52 million for the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative return on equity of 9.48% and a negative net margin of 18.96%. During the same quarter in the prior year, the company posted ($0.04) earnings per share. Analysts forecast that Amarin Co. plc will post -0.19 EPS for the current year.

Amarin Company Profile

(Free Report)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

See Also

Want to see what other hedge funds are holding AMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amarin Co. plc (NASDAQ:AMRNFree Report).

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.